BRIDGETOWER-CAPITAL
23.3.2022 17:05:05 CET | Business Wire | Press release
BridgeTower Capital, an innovator in connecting blockchain markets globally, is partnering with Securitize, the leader in digital assets securities, to launch the BridgeTower Global Platform offering for Permissioned Markets. BridgeTower is also launching a Staked Digital Asset Security (SDAS) that will run in an Avalanche subnet .
BridgeTower is partnering with Securitize, its digital transfer agent, to offer its products through a seamless user interface. Investors simply need to create a Securitize iD, in which their identity is verified consistent with U.S. regulatory standards. They can then invest easily in opportunities across the BridgeTower ecosystem, as well as Securitize’s own offerings, including shares in private companies and institutional grade funds.
Transactions will utilize smart contracts and regulated custodians will provide transparency around asset collateralization using Chainlink Proof of Reserve, the market-leading oracle solution for auditing on-chain and off-chain reserves. Using Chainlink Proof of Reserve to verify the collateral of wrapped tokens across the multi-chain ecosystem, BridgeTower’s Permissioned Markets will unlock asset liquidity across many of the world’s most significant blockchains.
BridgeTower’s Permissioned markets will include DeFi financial products such as customized blockchain staking opportunities, token swaps and NFT development with arts, entertainment, and sporting ventures to provide seamless, institutionally compliant products.
With more than 5,000 of its own Staking Nodes, BridgeTower utilizes renewable energy to reduce the carbon footprint. Already a leading proof-of-stake infrastructure provider for leading Layer 1 blockchains and Web 3.0 companies, BridgeTower has built its fast-growing foundational staking and DeFi business through partnerships and investments over the past few years.
“We are bridging the value of innovative blockchain staking and DeFi products seamlessly to institutional investors,” said BridgeTower CEO Cory Pugh. “We have worked tirelessly to bring innovation and regulated processes by using our staking and DeFi products in Permissioned Markets to create a compliant gateway for institutions to participate in the evolving blockchain opportunity.”
“There is significant institutional demand to participate in DeFi opportunities, but the lack of safe places to participate has kept institutions on the sidelines. Now that Securitize is offering permissioned DeFi through on-chain attestations, as well as through our partnership with Avalanche to build a permissioned subnet, the doors to regulated DeFi have opened,” said Jamie Finn, president, and co-founder of Securitize. “The globally integrated platform BridgeTower has created will enable more institutions to enter the market confidently.”
AVAX STAKED DIGITAL ASSET SECURITY TO LAUNCH
"Avalanche has rapidly become the preferred destination for institutions to access the innovation emerging from decentralized finance and contribute their own expertise in creating products and ecosystems of value on-chain. I'm excited to see BridgeTower and Securitize expanding their involvement in the Avalanche community and building institutional-grade applications," said John Nahas, VP of Business Development at Ava Labs.
BridgeTower’s most recent product innovation is a Staked Digital Asset Security. The new security will receive staking rewards, and after one year’s hold time can be traded in the Permissioned Market. The AVAX Staking Security token will represent staked AVAX utilizing Smart Contracts, to mint staked utility tokens on the Avalanche Chain and run across a subnet. This will create a single digital asset security designed for institutional investors capable of administering KYC, whitelisting, cap table management and reporting. BridgeTower will launch additional products later this year.
The Digital Staking Asset AVAX Security will also be offered on the Securitized Markets Alternative Trading System making it available to a wide range of accredited investors. Currently, there are more than 400,000 investors participating in Securitize Markets. Eventually, it is expected that the AVAX Staked Digital Asset Security, and other Institutional-grade staking securities will also be offered on Layer 1, Web 3.0, and eventually other exchanges.
“We believe this product is unique, as a security, and will be attractive to institutional investors who are looking for a regulated, global security to participate in the dramatically expanding blockchain proof-of-stake market,” Pugh added. “We are thrilled to partner with Securitize and Avalanche and for the expertise they bring as industry leaders in their respective areas.”
About BridgeTower
BridgeTower Capital has developed a global platform to uniquely bring products to its own permissioned markets to seamlessly enable an institutional gateway to staking, DeFi, NFT and Web 3.0 entities. BridgeTower operates more than 5,000 of its own staking nodes and owns servers utilizing 100 percent renewable energy. Significant portions of returns from these products are reinvested to continually grow BridgeTower’s infrastructure and assets. BridgeTower is a global company based in Singapore with operating entities in Switzerland and the United States allowing it to compliantly address many of the most important jurisdictions in the global economy. Learn more at http://www.bridgetowercapital.com .
About Securitize
Securitize is a digital asset securities firm with a mission to provide stakeholders access to invest in and trade alternative investments, and for companies to raise capital, manage shareholders, and offer shareholders potential liquidity. Securitize has pioneered a fully digital, end-to-end platform for issuing, managing, and trading digital asset securities, consistent with the existing U.S. regulatory framework, with over 1.2 million investor accounts and 3,000 businesses connected. Securitize is comprised of Securitize, Inc. and its subsidiaries Securitize, LLC (an SEC-registered transfer agent), Securitize Capital, LLC, Securitize Markets, LLC (an SEC-registered broker-dealer, member of FINRA and SIPC , and operator of the company’s alternative trading system), and Pacific Stock Transfer. Learn more at http://www.securitize.io .
About Avalanche
Avalanche is the fastest smart contracts platform in the blockchain industry, as measured by time-to-finality. Avalanche is blazingly fast, low cost, and eco-friendly. Any smart contract-enabled application can outperform its competition by deploying on Avalanche. Don’t believe it? Try an app on Avalanche today.
Securitize Disclosures
Securities offered on the Securitize Markets ATS have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Assets listed herein, such as digital assets or tokens using blockchain, are speculative, involve a high degree of risk, are generally illiquid, may have no value, have limited regulatory certainty, are subject to potential market manipulation risks and may expose investors to loss of principal. Blockchain investing involves a degree of risk that can be different from traditional markets. These risks include, but are not limited to, risk of regulatory uncertainty, market adoption, market manipulation, market exiting, price volatility and security risk. Investments in private placements, start-up investments in particular, are also speculative and involve a high degree of risk. Investors must be able to afford the loss of their entire investment. Eligibility to buy and sell securities on the Securitize Markets ATS is determined by Securitize Markets in its sole discretion. Offers to sell, or the solicitations of offers to buy any security can only be made through official offering documents that contain important information about risks, fees and expenses associated with the applicable securities available for trading on the Securitize Markets ATS. Investors should conduct their own due diligence, and are encouraged to consult with a financial advisor, attorney, accountant, tax advisors, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Past performance is not indicative of future results. There is no guarantee that a diversified portfolio will enhance overall returns, outperform a non-diversified portfolio, or prevent against loss
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom